US · SMTI · MEDICAL - INSTRUMENTS & SUPPLIES
Sanara MedTech Inc. (SMTI) intrinsic value and stock valuation
$32.55as of 2026-11-21 · Mkt cap 313.48M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Sanara MedTech Inc. DCF and intrinsic value
InvestorsCraft values SMTI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SMTI’s statements →
Sanara MedTech Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- NeoGenomics, Inc. (NEO) $14.82
- Viemed Healthcare, Inc. (VMD) $8.52
- Sight Sciences, Inc. (SGHT) $10.18
- Entrada Therapeutics, Inc. (TRDA) $4.35
- High Tide Inc. (HITI) $2.23
- LifeMD, Inc. (LFMD) $1.45
- Exagen Inc. (XGN) $3.61
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $103.1M | $86.7M | $65M | $45.8M | $24.1M |
| Operating income | $9.15M | -$-6.72M | -$-4.22M | -$-12.52M | -$-7.38M |
| Net income | -$-37.56M | -$-9.66M | -$-4.3M | -$-7.94M | -$-7.92M |
| EPSd | -$-4.36M | -$-1.14M | -$-519.32K | -$-1M | -$-1.08M |
| Operating cash flow | $6.79M | -$-20K | -$-3.25M | -$-5.55M | -$-4.81M |
| Capital expenditure | -$-4.63M | -$-230K | -$-270K | -$-750K | -$-750K |
| Free cash flow | $2.16M | -$-250K | -$-3.51M | -$-6.3M | -$-5.56M |
| Total assets | $72.9M | $88.1M | $73.9M | $61M | $36.4M |
| Total debt | $48.2M | $32.3M | $11.8M | $820K | $430K |
| Net debt | $31.6M | $16.4M | $6.64M | -$-8.14M | -$-18.23M |
| Total equity | $5.93M | $38.9M | $44.6M | $41.7M | $30.2M |
| Cash and short-term investments | $16.6M | $15.9M | $5.15M | $8.96M | $18.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $103.1M | $86.7M | $65M | $45.8M | $24.1M |
| Cost of revenue | $10.2M | $8.14M | $7.85M | $6.36M | $2.31M |
| Gross profit | $92.9M | $78.5M | $57.1M | $39.5M | $21.8M |
| Research and development expenses | $5.07M | $5.7M | $4.13M | $3.37M | $560K |
| Selling, general and administrative expenses | $78.7M | $76.6M | $57M | $46M | $28.1M |
| Other expenses | $0.00 | $2.98M | $230K | $2.66M | $600K |
| Operating expenses | $83.8M | $85.3M | $61.4M | $52M | $29.2M |
| Cost and expenses | $94M | $93.4M | $69.2M | $58.4M | $31.5M |
| Interest income | $0.00 | $20K | $0.00 | $280K | $0.00 |
| Interest expense | $6.76M | $3.13M | $480K | $280K | $0.00 |
| Depreciation and amortization | $2.66M | $4.92M | $3.68M | $2.37M | $770K |
| Ebitda | $9.03M | -$-1.86M | -$-290K | -$-11.57M | -$-7.22M |
| Operating income | $9.15M | -$-6.72M | -$-4.22M | -$-12.52M | -$-7.38M |
| Total other income/expenses, net | -$-9.54M | -$-3.2M | -$-220K | -$-1.42M | -$-620K |
| Income before tax | -$-390K | -$-9.91M | -$-4.44M | -$-13.94M | -$-7.99M |
| Income tax expense | $0.00 | $0.00 | $0.00 | -$-5.84M | $0.00 |
| Net income | -$-37.56M | -$-9.66M | -$-4.3M | -$-7.94M | -$-7.92M |
| Weighted average shares outstanding | $8.62M | $8.48M | $8.28M | $7.91M | $7.34M |
| Weighted average diluted shares outstanding | $8.62M | $8.48M | $8.28M | $7.91M | $7.34M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $16.6M | $15.9M | $5.15M | $8.96M | $18.7M |
| Net receivables | $12M | $13.6M | $8.53M | $7M | $2.99M |
| Inventory | $3.95M | $2.75M | $4.72M | $3.55M | $2.05M |
| Total current assets | $33.5M | $33.3M | $19M | $20.6M | $24.6M |
| Property, plant and equipment, net | $2.53M | $1.88M | $3.25M | $2.22M | $2.04M |
| Goodwill and intangible assets | $22.2M | $44.6M | $48.5M | $35.1M | $4.73M |
| Long-term investments | $14.6M | $8.3M | $3.08M | $3.08M | $5.02M |
| Total non-current assets | $39.4M | $54.8M | $54.9M | $40.4M | $11.8M |
| Total assets | $72.9M | $88.1M | $73.9M | $61M | $36.4M |
| Accounts payable | $2.34M | $1.5M | $2M | $1.43M | $590K |
| Short-term debt | $350K | $360K | $940K | $310K | $200K |
| Deferred revenue | $1.23M | $0.00 | $2.05M | $0.00 | $0.00 |
| Total current liabilities | $18.6M | $15.3M | $13.8M | $12.8M | $6.02M |
| Long-term debt | $47.8M | $31.9M | $10.9M | $510K | $220K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $48.4M | $33.9M | $15.5M | $6.51M | $220K |
| Capital lease obligations | $1.87M | $1.6M | $2.1M | $820K | $430K |
| Total liabilities | $67M | $49.2M | $29.3M | $19.3M | $6.24M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-75.3M | -$-37.78M | -$-28.04M | -$-23.39M | -$-15.24M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $5.93M | $38.9M | $44.6M | $41.7M | $30.2M |
| Total investments | $14.6M | $8.3M | $3.08M | $3.08M | $5.02M |
| Total debt | $48.2M | $32.3M | $11.8M | $820K | $430K |
| Net debt | $31.6M | $16.4M | $6.64M | -$-8.14M | -$-18.23M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-27.66M | -$-9.91M | -$-4.44M | -$-8.09M | -$-7.99M |
| Depreciation and amortization | $28.6M | $4.92M | $3.68M | $2.37M | $600K |
| Stock-based compensation | $720K | $4.44M | $3.44M | $2.7M | $2.67M |
| Change in working capital | -$-3.84M | -$-910K | -$-3.28M | $520K | -$-1.18M |
| Accounts receivable | $4.03M | -$-4.54M | -$-1.73M | -$-2.27M | -$-770K |
| Inventory | -$-430K | $1.44M | -$-1.55M | -$-520K | -$-1.15M |
| Accounts payable | $1.24M | -$-470K | $580K | -$-420K | $100K |
| Net cash provided by operating activities | $6.79M | -$-20K | -$-3.25M | -$-5.55M | -$-4.81M |
| Investments in property, plant and equipment | -$-4.42M | -$-210K | -$-270K | -$-150K | -$-170K |
| Acquisitions, net | $0.00 | $0.00 | -$-9.94M | -$-2.52M | $0.00 |
| Net cash used for investing activities | -$-8.36M | -$-6.61M | -$-10.21M | -$-3.51M | -$-5.28M |
| Common stock issued | $0.00 | $0.00 | $910K | $0.00 | $28.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-8.48M | $17.4M | $9.64M | -$-630K | $28.3M |
| Net change in cash | -$-10.03M | $10.7M | -$-3.81M | -$-9.69M | $18.2M |
| Cash at end of period | $700K | $15.9M | $5.15M | $8.96M | $18.7M |
| Operating cash flow | $6.79M | -$-20K | -$-3.25M | -$-5.55M | -$-4.81M |
| Capital expenditure | -$-4.63M | -$-230K | -$-270K | -$-750K | -$-750K |
| Free cash flow | $2.16M | -$-250K | -$-3.51M | -$-6.3M | -$-5.56M |
Line items
Line items
Line items
About Sanara MedTech Inc.
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
- CEO
- Seth D. Yon
- Employees
- 108
- Beta
- 1.18
Explore
Frequently asked questions
What is the intrinsic value of Sanara MedTech Inc. (SMTI)?
InvestorsCraft does not currently publish an intrinsic value for SMTI. How the IC value is calculated.
Is SMTI undervalued?
InvestorsCraft does not publish an undervaluation signal for SMTI at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.